Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of DLYE5953A in refractory solid tumors
NCT02092792Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2014
- Primary completion
- Jul 2017
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DLYE5953A in solid tumor, breast cancer and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genentech. Primary endpoints: Incidence of dose-limiting toxicities at 21 days and Incidence of adverse events at 32 months. Started Apr 2014; status: completed.
02
Drugs
DLYE5953A
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02092792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092792.